The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy
Authors:
- Sophia Po-Yee LeungSophia Po-Yee Leung
- Scott DoughertyScott Dougherty
- Xiao-Yu ZhangXiao-Yu Zhang
- Kevin K. H. KamKevin K. H. Kam
- Wai-Kin ChiWai-Kin Chi
- Joseph Y. S. ChanJoseph Y. S. Chan
- Erik FungErik Fung
- Jeffrey K. T. WongJeffrey K. T. Wong
- Paul C. L. ChoiPaul C. L. Choi
- David K. H. ChanDavid K. H. Chan
- Bun ShengBun Sheng
- Alex Pui-Wai LeeAlex Pui-Wai Lee
Open Access
- 2 July 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3896
Abstract
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder that commonly manifests cardiovascular complications. We aimed to assess the prevalence of FD in a Chinese population with left ventricular hypertrophy (LVH) whilst implementing a gender-specific screening approach. Methods: Patients with LVH, defined as a maximum thickness of the left ventricular septal/posterior wall ≥ 13 mm, were considered eligible. All patients with hypertrophic cardiomyopathy (HCM) were excluded. Plasma α-galactosidase (α-GLA) enzyme activity was assessed using a dried blood spot test. Males with low enzyme activity underwent genetic testing to confirm a diagnosis of FD whereas females were screened for both α-GLA and globotriaosylsphingosine concentration and underwent genetic analysis of the GLA gene only if testing positive for ≥1 parameter. Results: 426 unrelated patients (age = 64.6 ± 13.0 years; female: male = 113:313) were evaluated. FD was diagnosed in 3 unrelated patients (age = 69.0 ± 3.5 years, female: male = 1:2) and 1 related female subject (age = 43 years). Genetic analyses confirmed the late-onset cardiac variant GLA c.640-801G>A (n = 3) and the missense variant c.869T>C associated with classic FD (n = 1). Cardiac complications were the only significant findings associated with the late-onset c.640-801G>A mutation, manifesting as mild or severe concentric LVH. In contrast, the classic c.869T>C mutation FD exhibited multisystemic manifestations in addition to severe concentric LVH. Conclusions: The prevalence of FD is lower in Chinese patients with LVH when HCM is excluded. The pathological variant c.640-801G>A remains the most common cause of late-onset FD, while the detection of FD in females can be improved by utilizing a gender-specific screening method.Keywords
Funding Information
- Sanofi
This publication has 53 references indexed in Scilit:
- Late-onset fabry disease due to the p.Phe113Leu variant: the first italian cluster of five familiesMetabolic Brain Disease, 2023
- Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis)The International Journal of Cardiovascular Imaging, 2023
- Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic CardiomyopathyThe American Journal of the Medical Sciences, 2021
- Global research on Fabry's disease: Demands for a rare diseaseMolecular Genetics & Genomic Medicine, 2020
- Strong increase of leukocyte apha‐galactosidase A activity in two male patients with Fabry disease following oral chaperone therapyMolecular Genetics & Genomic Medicine, 2019
- Fabry disease in cardiology practice: Literature review and expert point of viewArchives of Cardiovascular Diseases, 2019
- Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic CardiomyopathyThe American Journal of Medicine, 2018
- Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical MyectomyJAMA Cardiology, 2017
- Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)Journal of Inherited Metabolic Disease, 2013
- Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onsetGLAmutation c.936+919G>A (IVS4+919G>A)Human Mutation, 2009